PMID- 27104338
OWN - NLM
STAT- MEDLINE
DCOM- 20171023
LR  - 20181113
IS  - 2164-554X (Electronic)
IS  - 2164-5515 (Print)
IS  - 2164-5515 (Linking)
VI  - 12
IP  - 9
DP  - 2016 Sep
TI  - Phosphate substitution in an AlOOH - TLR4 adjuvant system (SPA08) modulates the 
      immunogenicity of Serovar E MOMP from Chlamydia trachomatis.
PG  - 2341-50
LID - 10.1080/21645515.2016.1168958 [doi]
AB  - Chlamydia trachomatis is one of the most common sexually transmitted pathogens 
      and the development of an effective vaccine is highly desirable. The Major Outer 
      Membrane Protein (MOMP) is one of the most abundant and immunogenic chlamydial 
      proteins. Here we investigated the effects of phosphate substitution on the 
      physicochemical and immunochemical properties of an experimental vaccine composed 
      of serovar E recombinant MOMP (rMOMP) and a proprietary adjuvant system SPA08, 
      consisting of aluminum oxyhydroxide (AlOOH) containing the TLR4 agonist E6020. An 
      increase in phosphate substitution in the AlOOH component of the adjuvant 
      markedly decreased the adsorptive coefficient and adsorptive capacity for both 
      Ser E rMOMP and E6020. In vaccine formulations used for immunizations, phosphate 
      substitution induced a decrease in the % adsorption of Ser E rMOMP without 
      affecting the % adsorption of E6020. Immunogenicity studies in CD1 mice showed 
      that an increase in phosphate substitution of the SPA08 adjuvant resulted in an 
      increase in Ser E rMOMP-specific serum total IgG and IgG1 but not IgG2a titers. 
      The degree of phosphate substitution in SPA08 also significantly increased in 
      vitro neutralization concomitant with a decrease in proinflammatory cytokines 
      secreted by Ser E rMOMP-restimulated splenocytes. Taken together, the results of 
      these studies suggest that the degree of phosphate substitution in AlOOH greatly 
      affects the adsorption of E6020 and Ser E rMOMP to AlOOH resulting in significant 
      effects on vaccine-induced cellular and humoral responses.
FAU - Visan, Lucian
AU  - Visan L
AD  - a Research & Non Clinical Safety Department , Sanofi Pasteur , Marcy l'Etoile , 
      France.
FAU - Sanchez, Violette
AU  - Sanchez V
AD  - a Research & Non Clinical Safety Department , Sanofi Pasteur , Marcy l'Etoile , 
      France.
FAU - Kania, Margaux
AU  - Kania M
AD  - b Bioprocess Research and Development, Sanofi Pasteur , Toronto , ON , Canada.
FAU - de Montfort, Aymeric
AU  - de Montfort A
AD  - a Research & Non Clinical Safety Department , Sanofi Pasteur , Marcy l'Etoile , 
      France.
FAU - de la Maza, Luis M
AU  - de la Maza LM
AD  - c Department of Pathology and Laboratory Medicine , Medical Sciences I, 
      University of California , Irvine , CA , USA.
FAU - Ausar, Salvador Fernando
AU  - Ausar SF
AD  - b Bioprocess Research and Development, Sanofi Pasteur , Toronto , ON , Canada.
LA  - eng
PT  - Journal Article
DEP - 20160422
PL  - United States
TA  - Hum Vaccin Immunother
JT  - Human vaccines & immunotherapeutics
JID - 101572652
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antibodies, Bacterial)
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Bacterial Outer Membrane Proteins)
RN  - 0 (Bacterial Vaccines)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Phosphates)
RN  - 0 (Tlr4 protein, mouse)
RN  - 0 (Toll-Like Receptor 4)
RN  - 0 (Vaccines, Subunit)
RN  - 0 (Vaccines, Synthetic)
RN  - 5QB0T2IUN0 (Aluminum Hydroxide)
RN  - 63957-70-0 (aluminum oxide hydroxide)
RN  - LMI26O6933 (Aluminum Oxide)
SB  - IM
MH  - Adjuvants, Immunologic/*administration & dosage
MH  - Aluminum Hydroxide/*administration & dosage
MH  - Aluminum Oxide/*administration & dosage
MH  - Animals
MH  - Antibodies, Bacterial/blood
MH  - Antibodies, Neutralizing/blood
MH  - Bacterial Outer Membrane Proteins/administration & dosage/genetics/*immunology
MH  - Bacterial Vaccines/administration & dosage/genetics/*immunology
MH  - Chlamydia trachomatis/*immunology
MH  - Female
MH  - Immunoglobulin G/blood
MH  - Mice
MH  - Phosphates/*administration & dosage
MH  - Toll-Like Receptor 4/*administration & dosage
MH  - Vaccines, Subunit/administration & dosage/genetics/immunology
MH  - Vaccines, Synthetic/administration & dosage/genetics/immunology
PMC - PMC5027717
OTO - NOTNLM
OT  - Chlamydia trachomatis
OT  - IgG response
OT  - MOMP
OT  - T cell response
OT  - TLR4 agonist
OT  - aluminum hydroxide adjuvant
OT  - immunomodulation
OT  - phosphate substitution
OT  - vaccine
EDAT- 2016/04/23 06:00
MHDA- 2017/10/24 06:00
PMCR- 2017/04/22
CRDT- 2016/04/23 06:00
PHST- 2016/04/23 06:00 [entrez]
PHST- 2016/04/23 06:00 [pubmed]
PHST- 2017/10/24 06:00 [medline]
PHST- 2017/04/22 00:00 [pmc-release]
AID - 1168958 [pii]
AID - 10.1080/21645515.2016.1168958 [doi]
PST - ppublish
SO  - Hum Vaccin Immunother. 2016 Sep;12(9):2341-50. doi: 
      10.1080/21645515.2016.1168958. Epub 2016 Apr 22.